Establishment Labs to Present at 44th Annual J.P. Morgan Healthcare Conference
ESTANEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced that Peter Caldini, Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, will present at the 44th Annual J.P Morgan Healthcare Conference on January 14, 2026 at 9:45 a.m. PT. A live webcast of the presentation will be available on the Establishment Labs
Establishment Labs Reports Second Quarter 2025 Financial Results
ESTANEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the second quarter ended June 30, 2025. Second Quarter Highlights and Outlook (Unaudited) Second quarter worldwide revenue of $51.3 million, an increase of 16.3% from the year ago period. Revenue included $10.3 million of Motiva sales in the Un
Establishment Labs Hosting Investor Day on June 12
ESTANEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, will host its previously announced analyst and investor event in New York City on June 12, 2025 beginning at 1pm ET. A live and archived webcast of presentations and Q&A sessions on June 12 will be available on the Investors section of the Establishment Labs website at www.es
Needham Upgrades Establishment Labs Hldgs to Buy, Announces $48 Price Target
ESTAEstablishment Labs Hldgs Affirms FY2025 Sales Guidance of $205.00M-$210.00M vs $206.92M Est
ESTAEstablishment Labs Hldgs Q1 EPS $(0.70) Beats $(0.81) Estimate, Sales $41.38M Beat $41.11M Estimate
ESTAEstablishment Labs Holdings Appoints Peter Caldini As CEO, Effective May 7, 2025
ESTACorrection: Needham Initiates Coverage On Establishment Labs Hldgs to Hold (Rating Change From Reiterate to Initiates)
ESTANeedham Reiterates Hold on Establishment Labs Hldgsto Hold
ESTAEstablishment Labs Holdings Sees Prelim. Q1 Revenue ~$41.4M Vs $40.762M Est.
ESTAStephens & Co. Reiterates Overweight on Establishment Labs Hldgs, Maintains $52 Price Target
ESTAEstablishment Labs Hldgs Affirms FY2025 Sales Guidance of $205.00M-$210.00M vs $206.24M Est
ESTAEstablishment Labs Hldgs Q4 EPS $(1.19) Misses $(0.62) Estimate, Sales $44.51M Miss $44.61M Estimate
ESTAEstablishment Labs Announces Peter Caldini To Become Interim CEO Effective March 1, 2025; Anticipates 2024 Revenue Between $166M-$166.5M, Q4 Revenue Between $44.5M-$45M; $3.2M From U.S. Motiva Sales
ESTAExploring Establishment Labs Hldgs's Earnings Expectations
ESTAEstablishment Labs Announces 3-Year Mia Femtech Clinical Results At 9th World Symposium On Ergonomic Implants; There Were Also No Reports Of Infection, Hematoma, Or Seroma Requiring Intervention In The Study And No Reports Of Changes In Nipple Or Breast S
ESTAThe Analyst Landscape: 5 Takes On Establishment Labs Hldgs
ESTACitigroup Downgrades Establishment Labs Hldgs to Neutral, Maintains Price Target to $60
ESTA